Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10–17 years of age: Results from a randomised, controlled, double-blind trial

Overview of attention for article published in Vaccine, July 2013

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (79th percentile)
Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

twitter: 1 X user

patent: 4 patents

Citations

dimensions_citation: 16 Dimensions

Readers on

mendeley: 58 Mendeley

Summary X Patents Dimensions citations

So far, Altmetric has seen 4 patents that reference this research output.

RECOMBINANT HERPES SIMPLEX VIRUS 2 (HSV-2) VECTORS AND ENGINEERED TRANSGENIC VERO CELL…

Application WO-2023245159-A1

World Intellectual Property Organisation (WIPO)

RECOMBINANT HERPES SIMPLEX VIRUS 2 (HSV-2) VACCINE VECTORS

Application EP-3943106-A1

European Patent Office

PASSIVE TRANSFER OF IMMUNITY USING RECOMBINANT HERPES SIMPLEX VIRUS 2 (HSV-2) VACCINE…

Application WO-2020142677-A1

World Intellectual Property Organisation (WIPO)

RECOMBINANT HERPES SIMPLEX VIRUS 2 (HSV-2) VACCINE VECTORS

Application WO-2015134368-A2

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.